{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Patrick+Grady&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Jo+Churchill&questionText=To+ask+the+Secretary+of+State+for+Health+and+Social+Care%2C+what+assessment+his+Department+has+made+of+the+potential+merits+of+using+camostat+mesylate+in+the+treatment+of+patients+with+covid-19.", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Patrick+Grady&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Jo+Churchill&questionText=To+ask+the+Secretary+of+State+for+Health+and+Social+Care%2C+what+assessment+his+Department+has+made+of+the+potential+merits+of+using+camostat+mesylate+in+the+treatment+of+patients+with+covid-19.", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Patrick+Grady&_metadata=all&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Jo+Churchill&questionText=To+ask+the+Secretary+of+State+for+Health+and+Social+Care%2C+what+assessment+his+Department+has+made+of+the+potential+merits+of+using+camostat+mesylate+in+the+treatment+of+patients+with+covid-19.", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Patrick+Grady&_page=0&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Jo+Churchill&questionText=To+ask+the+Secretary+of+State+for+Health+and+Social+Care%2C+what+assessment+his+Department+has+made+of+the+potential+merits+of+using+camostat+mesylate+in+the+treatment+of+patients+with+covid-19.", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Patrick+Grady&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Jo+Churchill&questionText=To+ask+the+Secretary+of+State+for+Health+and+Social+Care%2C+what+assessment+his+Department+has+made+of+the+potential+merits+of+using+camostat+mesylate+in+the+treatment+of+patients+with+covid-19.", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Patrick+Grady&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Jo+Churchill&questionText=To+ask+the+Secretary+of+State+for+Health+and+Social+Care%2C+what+assessment+his+Department+has+made+of+the+potential+merits+of+using+camostat+mesylate+in+the+treatment+of+patients+with+covid-19.", "items" : [{"_about" : "http://data.parliament.uk/resources/1192284", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1192284/answer", "answerText" : {"_value" : "<p>There are currently no approved treatments for COVID-19 and full evaluation of the merits of any potential treatments can only be made once clinical trials involving COVID-19 patients have been completed. The United Kingdom Government is considering a wide range of potential treatments in the current UK clinical trials. Drugs representing a range of relevant modes of action including - but not limited to - serine protease inhibitors, such as camostat, are being reviewed and prioritised by a panel of experts so that the most promising are put into clinical trials first.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2020-05-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1192284/answer/previousversion/19579", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
          }
          , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
          , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        }
        , "questionFirstAnswered" : [{"_value" : "2020-05-15T11:25:11.047Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2020-05-01", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Coronavirus: Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using camostat mesylate in the treatment of patients with covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4432", "label" : {"_value" : "Biography information for Patrick Grady"}
      }
      , "tablingMemberConstituency" : {"_value" : "Glasgow North"}
      , "tablingMemberPrinted" : [{"_value" : "Patrick Grady"}
      ], "uin" : "42092"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}